In relapsed pediatric acute lymphoblastic leukemia (ALL) patients, SETD2 mutations were found at an increased frequency, highlighting a possible role of SETD2 in chemotherapy resistance [10]. This evidence concerns the gene SETD2 and acute lymphoblastic leukemia.